Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact will focus on the TransCon technology platform to develop, manufacture, and commercialize Novo Nordisk proprietary products for metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license for cardiovascular diseases.
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk's blockbuster GLP-1 drugs to treat type 2 diabetes and obesity, including Wegovy and Ozempic, continued to drive the company's growth in the quarter, Sydbank senior analyst Soren Lontoft Hansen said in a note.
Novo Nordisk Posts Solid Earnings. Weight-Loss Drug Wegovy Sales Beat Estimates.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. W
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced drug delivery technology.
New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity
Novo Nordisk's (NVO) semaglutide, marketed as Wegovy for obesity, shows promise in reducing joint disease symptoms in addition to weight loss. Read more here.
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
Key Takeaways Danish pharmaceutical giant Novo Nordisk is set to report earnings for the third quarter of 2024 on Wednesday morning.Sales of its popular weight-loss drugs Ozempic and Wegovy will be Novo investors' focus.
Ozempic, Wegovy ingredient may lower risk of Alzheimer’s, study finds
Ever since their rise in popularity as weight loss drugs, there’s been a slew of reports on the potential adverse health ...
Novo Nordisk’s Wegovy sales jump on international rollouts
Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.
pharmaphorum1h
Wegovy romps ahead after key rival sees slowdown
GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
Medical News Today15h
Can Ozempic and Wegovy help reduce knee osteoarthritis-related pain?
Medications like Ozempic and Wegovy, which are used to treat type 2 diabetes and boost weight loss, may also help reduce knee ...
Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
Where to Buy Wegovy from Reputable Online Providers
Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on ...
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
CNBC on MSN3h
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...